ERBB2 and breast cancer: In our study, the distribution of molecular subtypes among young women with breast cancer was as follows: luminal A subtype accounted for 14.5%, luminal B subtype for 45.8%, HER2+ subtype for 18.4%, and TNBC for 21.3%.